Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 3,957 Shares of Stock

Key Points

• Insider sale: Nurix Therapeutics insider Gwenn Hansen sold 3,957 shares for approximately $104,000 under a pre-arranged Rule 10b5-1 plan to cover tax withholding tied to vested equity awards. Hansen retained 123,452 shares.
• Stock and earnings: NRIX recently traded at $25.70, with a market capitalization of about $2.81 billion. The company reported quarterly EPS of $4.73, substantially above the $0.60 loss analysts expected, alongside $673.06 million in revenue.
• Analyst outlook: Wall Street maintains a consensus “Moderate Buy” rating, with 13 Buy, one Hold, and one Sell recommendation. The average analyst price target is $34.79, above the recent trading price.

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) insider Gwenn Hansen sold 3,957 shares of the company's stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $26.28, for a total transaction of $103,989.96. Following the sale, the insider directly owned 123,452 shares of the company's stock, valued at $3,244,318.56. This represents a 3.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Gwenn Hansen also recently made the following trade(s):

• On Monday, November 2nd, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The stock was sold at an average price of $26.80, for a total transaction of $38,913.60.
• On Thursday, October 15th, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $36,300.00.
• On Tuesday, September 1st, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.47, for a total transaction of $36,982.44.
• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.00, for a total value of $108,900.00.
• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.36, for a total transaction of $100,143.96.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock traded down $1.10 during trading hours on Monday, reaching $25.70. The company had a trading volume of 2,348,532 shares, compared to its average volume of 2,495,734. Nurix Therapeutics, Inc. has a one year low of $11.67 and a one year high of $28.23. The business has a fifty day simple moving average of $24.98 and a 200 day simple moving average of $20.20. The firm has a market cap of $2.81 billion, a PE ratio of 11.80 and a beta of 1.82.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings results on Monday, October 12th. The company reported $4.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.60) by $5.33. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. The firm had revenue of $673.06 million for the quarter, compared to the consensus estimate of $24.35 million. On average, research analysts forecast that Nurix Therapeutics, Inc. will post 1.14 EPS for the current year.

Institutional Investors Weigh In On Nurix Therapeutics

Hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Nurix Therapeutics in the 3rd quarter valued at approximately $126,000. China Universal Asset Management Co. Ltd. increased its position in Nurix Therapeutics by 15.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,936 shares of the company's stock valued at $448,000 after acquiring an additional 2,479 shares during the period. Sterling Capital Management LLC raised its stake in shares of Nurix Therapeutics by 310.4% during the third quarter. Sterling Capital Management LLC now owns 2,885 shares of the company's stock valued at $68,000 after purchasing an additional 2,182 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Nurix Therapeutics by 95.4% during the third quarter. GAMMA Investing LLC now owns 1,270 shares of the company's stock valued at $30,000 after acquiring an additional 620 shares during the period. Finally, Farther Finance Advisors LLC raised its stake in shares of Nurix Therapeutics by 755.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,014 shares of the company's stock worth $95,000 after buying an additional 3,545 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have commented on NRIX. Royal Bank Of Canada decreased their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 13th. Wall Street Zen raised Nurix Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, October 17th. UBS Group increased their price objective on Nurix Therapeutics from $23.00 to $31.00 and gave the stock a "buy" rating in a research report on Wednesday, July 22nd. Stifel Nicolaus set a $41.00 target price on Nurix Therapeutics in a research report on Tuesday, October 13th. Finally, HC Wainwright upped their target price on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a "buy" rating in a research report on Friday, October 16th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $34.79.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.

The company's pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton's tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.